B01 IL-35+ B cells establish immunosuppressive network in pancreatic ductal adenocarcinoma. Bhalchandra Mirlekar, Yuliya Pylayeva-Gupta. The Lineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill, Chapel Hill, NC.


B05 Targeting the chemokine receptor CCR4 using chimeric antigen receptor T cells for the treatment of CCR4+ T-cell malignancies. Marissa M. Del Real. City of Hope, Duarte, CA.

B07 Optical metabolic imaging and molecular profiling of immune-tumor cell interactions in 3D microfluidic models. Shujah H. Rehman. Morgridge Institute for Research, Madison, WI.


B09 Glioblastoma disguised: Combined therapy using CD19 expressing oncolytic adenovirus and CD19-targeted CAR T cells. Dong Ho Shin. The University of Texas MD Anderson Cancer Center, Houston, TX.

B10 Leveraging the multiparametric profiling by mass cytometry to identify and deeply characterize tumor-reactive T cells. David Roumanes. immunoSCAPE, Inc., Cambridge, MA.

B11 Immunopeptidomics and peptide expression profiles to develop T-cell receptors against glioma-associated antigens. Diego A. Carrera. University of California San Francisco, San Francisco, CA.

B12 Identifying and engineering TCR specificity against mutated self. Martin S. Naradikian. La Jolla Institute for Immunology, San Diego, CA.

B13 Associations of tumor-infiltrating lymphocytes and noncanonical NFkB proteins with the patient outcome. Mithalesh Kumar Singh. Dr. R.P. Centre of Ophthalmic Sciences, ALL India Institute of Medical Sciences, New Delhi, Delhi, India.

B14 Personalized gene editing of T cells to express neoantigen-specific TCRs isolated from peripheral blood of patients on PD-1 blockade therapy. Cristina Puig-Saus. Division of Hematology-Oncology, Department of Medicine, David Geffen School of Medicine (DGSOM), University of California, Los Angeles (UCLA), Los Angeles, CA.

B16 The effect of CTLA-4 blockade on the expansion of tumor-infiltrating lymphocytes for adoptive cell therapy in metastatic ovarian cancer. Christina Friese. Center for Cancer Immune Therapy, Department of Hematology, Herlev Hospital, Herlev, Denmark.


B20 Repurposing sildenafil as an immunotherapy agent in lung adenocarcinoma: Mechanism involved in FSTL1-BMP4-Smad-osteopontin axis. Jean Chioi_Academia Sinica, Taipei, Taiwan.

B21 Comparison of NGS-based HLA class I genotyping tools. Jeong-Han Seo. Asan Medical Center, Seoul, Korea.

B22 Common and specific target genes for knockout of MIR 196A1, A2, and B in colon cancer cells. JiSu Mo. Wonkwang University, Iksan, South Korea.

B23 MFN2 modulates thyroid cancer progression through mTORC2/AKT signaling. Mi-Hyeon You. University of Ulsan College of Medicine, Seoul, South Korea.


B25 Predicting CD19Neg relapse following CAR T-cell therapy in B-cell precursor acute lymphoblastic leukemia. Pablo Domizi. Department of Pediatrics, Bass Center for Childhood Cancer and Blood Disorders, Stanford University, Stanford, CA.


B27 RelB upregulates PD-L1 in advanced prostate cancer: An insight into tumor immunoescape. Yanyan Zhang. Affiliated Cancer Hospital of Nanjing Medical University, Nanjing, China, Nanjing Medical University, Nanjing, China, China Pharmaceutical University, Nanjing, China.